| US: Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind ...
Found: Mon May 21 04:56:13 2012 PDT
Webpage: http://www.sys-con.com/node/2281386
Author: Cloud Expo, Inc, info@peregrineinc.com
Newshawk: http://drugpolicycentral.com/bot/
| |
[ topical analysis ] propaganda analysis
* Advertise
* Webcasts
* Events
* Write An Article
SYS-CON MEDIA Authors: Bob Gourley, Greg Schulz, Kevin Remde, RealWire News Distribution, Phil Worms
News Feed Item
Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer
Bavituximab Plus Chemotherapy Demonstrates Doubling of Overall Response Rates Versus Chemotherapy Alone; 50% Improvement in Progression-Free Survival and Overall Survival Trends Support Phase III Development
By Marketwire .
Article Rating:
May 21, 2012 07:30 AM EDT
* Add This
* Blog This
TUSTIN, CA -- (Marketwire) -- 05/21/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase IIb trial evaluating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo (control arm) in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial showed a doubling of overall response rates (ORR), the primary endpoint, and an improvement in progression-free survival (PFS), a secondary endpoint, in patients treated in the bavituximab-containing arms when compared to the control arm. Another secondary endpoint, median overall survival (OS), in the control arm has already been determined at less than 6 months, while the median has not been reached in either bavituximab-containing arm.
Based on independent radiology reviews and current status of patients, top-line data from the trial are as follows:
"The compelling results from this rigorously designed trial clearly demonstrate that the combination of bavituximab and docetaxel is more active than docetaxel alone in treating second-line non-small cell lung cancer. We saw twice as many patients demonstrating an objective tumor response, increased progression-free survival, and already promising survival trends in this refractory setting. These results give us a high level of confidence as we begin planning for Phase III development in this indication," said Joseph Shan, vice president, clinical and regulatory affairs at Peregrine. "We now look forward with heightened enthusiasm to several clinical data points coming this year, including overall survival results from this and potentially two other randomized Phase II trials, as well as data from four ongoing investigator-sponsored trials evaluating new treatment combinations in various cancers."
Based on the review of safety and efficacy of this trial conducted by an independent Data Monitoring Committee, no significant safety issues or concerns were identified when comparing the bavituximab containing arms with the docetaxel alone arm.
This trial enrolled 121 patients with second-line Stage IIIb or IV (TNM Edition 7) non-squamous NSCLC following one prior chemotherapy regimen and were equally randomized to 1 of the 3 treatment arms, with 117 patients included in the top-line analysis. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Patients received up to 6 cycles of docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression.
"After working on over 17 drug approvals, it is data like this that continues to energize and excite me. These robust data will be important in discussions with the FDA regarding advancing bavituximab's clinical development in second-line non-small cell lung cancer," said Robert Garnick, PhD, head of regulatory affairs at Peregrine. "We look forward to working closely with the FDA to identify the most efficient path toward commercialization for this promising candidate in this indication where new therapies are desperately needed."
According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in the U.S., with approximately 226,160 new cases and 160,340 deaths each year, representing approximately 28% of all cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Unfortunately, the five-year survival rate for NSCLC patients is only 1%.
"These data are a significant validation of the clinical potential of bavituximab for patients with few effective treatment options. These data will be instrumental in planning Phase III development in NSCLC and we are excited to share these data as part of ongoing partnering discussions," said Steven W. King, president and chief executive officer of Peregrine. "We look forward to sharing even more clinical data points this year from all seven bavituximab studies aimed at highlighting the broad therapeutic potential of bavituximab across multiple oncology indications and treatment combinations thus potentially building even more value in the program."
About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in seven clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and four investigator-sponsored trials (ISTs) in additional oncology indications.
PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara .. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data together with the above reported data may not support registration filings with the U.S. Food and Drug Administration ("FDA"), the risk that results from the other randomized Phase II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2011 and the quarterly report on Form 10-Q for the quarter ended January 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
info@peregrineinc.com
Published May 21, 2012
Copyright (c) 2012 SYS-CON Media, Inc. - All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
* Related
* Print
* Email
* Add This
* Blog This
More Stories By Marketwire .
Copyright (c) 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
Comments
Big Data -- A Sea Change of Capabilities in IT
By Pat Romanski
Matt McLarty wrote: For more info... Follow me on Twitter See our website
May. 2, 2012 03:40 PM EDT
Cloud Expo on Google News
Did you read today's front page stories & breaking news?
Cloud Expo & Virtualization 2011 West
Keynotes
Oracle
Many Clouds, Many Choices'Cloud
PLATINUM PLUS SPONSORS:
Abiquo
Enterprise Cloud Best Practices - Town Hall - Join the discussion
PLATINUM SPONSORS:
Intel
Progressing Toward the Federated, Automated and Client-Aware Cloud
New Relic
Intel/McAfee
Identity Driven Security in the Cloud
PerspecSys
Hackers Hackers Everywhere, Is My Public Cloud That Safe?
Red Hat
Unlock the Value of the Cloud
SHI
Mission Critical Applications and the Cloud - Myth or Reality?
SoftLayer
Not Your Grandpa's Cloud
Terremark
Integrating Enterprise Clouds
Dell & VMware Deliver the Enterprise Hybrid Cloud
PLATINUM PLUS SPONSORS:
Abiquo
Are Financial Services Organizations Risking Security by Avoiding Cloud Computing?
Oracle
From Consolidation to Enterprise Private PaaS
PLATINUM SPONSORS:
Intel
Driving the Transformation to Next Generation Cloud Data Centers
Rackspace
The Inevitability of an Open Cloud
GOLD SPONSORS:
CA Technologies
PerspecSys
War in the Clouds: Are you ready?
ServiceMesh
The Big Win: Stop Playing Small-Ball with Your Cloud Strategy
Terremark
Evaluating Enterprise Clouds
Xiotech
Cloud Storage: Myths and Realities
ADS BY GOOGLE
Breaking Java News
Tyfone Announces NFC Design Breakthrough Associated Patents and Licensing
Research and Markets: Information Technology Litigation: Law and Analysis
Research and Markets: Programming the Payment: From APIs to Commerce Platforms
First Utility Launches UK's Cheapest Fixed Price Energy Deal
Research and Markets: Hosting & Cloud Providers in Europe - The Top 100
Try a New Approach to Forex Trading With Vantage FX UK
Pitney Bowes Provides Notice of Bond Repurchase
WaveMark Collaborates with UMass Lowell Engineering Team to Bring New RFID Product to Market
North Carolina State Highway Patrol Orders 422 TASER X2 ECDs
Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer
Cloud Expo
* Home
* Keynotes
* Speakers
* Media Sponsors
* Advisory Board
* Volunteers
Is Your Business 100% Ready for the New Era of Cloud Computing and Big Data?
The Only Enterprise IT Event in 2012 Covering the Entire Scope of both Cloud & Big Data
Come to New York and get yourself up to date with the Big Data revolution! As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the Cloud Computing boom, Cloud Expo is the single most effective event for you to learn how to use you own enterprise data -- processed in the Cloud -- most effectively to drive value for your business.
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Get a jump on that rapidly evolving trend at Big Data Expo, which we are introducing in June at Cloud Expo New York.
Cloud Expo was announced on February 24, 2007, the day the term "cloud computing" was coined. That same year, the first Cloud Expo took place in New York City with 450 delegates. Next June, Cloud Expo is returning to New York with more than 10,000 delegates and over 600 sponsors and exhibitors.
"Cloud" has become synonymous with "computing" and "software" in two short years. Cloud Expo is the new PC Expo, Comdex, and InternetWorld of our decade. By 2012, more than 50,000 delegates per year will participate in Cloud Expo worldwide.
The cloud is certainly a compelling alternative to running all applications within a traditional corporate data center. But moving from theory into practice is where things get complicated, and this is where attending a top industry event like Cloud Expo comes in.
No one can take full advantage of cloud computing without first becoming familiar with the latest issues and trends, which is why the organizing principle of the 10th International Cloud Conference & Expo on June 11-14, 2012 - is to ensure - through an intensive four-day schedule of keynotes, general and breakout sessions, and our bustling Expo Floor - that attending delegates leave the Javits Center with abundant resources, ideas and examples they can apply immediately to leveraging the Cloud, helping them to maximize performance, minimize cost and improve the scalability of their Enterprise IT endeavors.
Delegates will leave Cloud Expo with dramatically increased understanding the entire scope of the entire cloud computing spectrum from storage to security.
Whether you're an enterprise or small to medium business, you'll soon be benefiting from the Cloud. Join your peers in New York City June 11-14, and maximize those benefits already in 2012. See you in New York City!
Register Now!
Save $500 on your "Golden Pass"! Call 201.802.3020
or click here to Register
Early Bird Expires Friday.
Speaker Opportunities
Submit your speaking proposal for the upcoming Cloud Expo in New York City
[June 11-14, 2012]
Exhibitor Info
Please Call 201.802.3021
events (at) sys-con.com.
carmen (at) sys-con.com.
Produced and presented by Cloud Expo, Inc.
All Rights Reserved. All marks are trademarks of Ulitzer, Inc.
Reproduction in whole or in part in any form or medium without express written permission of Ulitzer, Inc. is prohibited.
close this window
| re:1.11 st:0.02 fo:0 s:0.02 d:2.25 c:0 db:0.456 a:1.46 m:0.37 t:15.64 (f) |
text of article used for CRITICAL ANALYSIS, under FAIR USE provisions of the Copyright Act of 1976, 17 U.S.C. § 107, et al.
| 
